These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 27397590)

  • 21. No evidence that pyrazinamide resistance is acquired after fluoroquinolone resistance.
    Cobelens F; Gebhard A; van den Hof S
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):282. PubMed ID: 26792486
    [No Abstract]   [Full Text] [Related]  

  • 22. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
    Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of Pyrazinamide Resistance in Khyber Pakhtunkhwa, Pakistan.
    Khan MT; Malik SI; Ali S; Sheed Khan A; Nadeem T; Zeb MT; Masood N; Afzal MT
    Microb Drug Resist; 2018 Nov; 24(9):1417-1421. PubMed ID: 29584579
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive).
    Ziganshina LE; Titarenko AF; Davies GR
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD004795. PubMed ID: 23744519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates.
    Mphahlele M; Syre H; Valvatne H; Stavrum R; Mannsåker T; Muthivhi T; Weyer K; Fourie PB; Grewal HM
    J Clin Microbiol; 2008 Oct; 46(10):3459-64. PubMed ID: 18753350
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In reply.
    Takiff H; Alame-Emane AK; Pierre-Audigier C; Gicquel B
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):282-3. PubMed ID: 26792487
    [No Abstract]   [Full Text] [Related]  

  • 27. Prevalence of drug-resistant tuberculosis and imputed burden in South Africa: a national and sub-national cross-sectional survey.
    Ismail NA; Mvusi L; Nanoo A; Dreyer A; Omar SV; Babatunde S; Molebatsi T; van der Walt M; Adelekan A; Deyde V; Ihekweazu C; Madhi SA
    Lancet Infect Dis; 2018 Jul; 18(7):779-787. PubMed ID: 29685458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New effective antituberculosis regimens.
    Sotgiu G; Migliori GB
    Lancet; 2015 May; 385(9979):1703-1704. PubMed ID: 25795077
    [No Abstract]   [Full Text] [Related]  

  • 29. Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand.
    Jonmalung J; Prammananan T; Leechawengwongs M; Chaiprasert A
    BMC Microbiol; 2010 Aug; 10():223. PubMed ID: 20727143
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay.
    Trollip AP; Moore D; Coronel J; Caviedes L; Klages S; Victor T; Romancenco E; Crudu V; Ajbani K; Vineet VP; Rodrigues C; Jackson RL; Eisenach K; Garfein RS; Rodwell TC; Desmond E; Groessl EJ; Ganiats TG; Catanzaro A
    Int J Tuberc Lung Dis; 2014 Feb; 18(2):227-32. PubMed ID: 24429318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group 222 Protocol Team.
    Perlman DC; El Sadr WM; Heifets LB; Nelson ET; Matts JP; Chirgwin K; Salomon N; Telzak EE; Klein O; Kreiswirth BN; Musser JM; Hafner R
    AIDS; 1997 Oct; 11(12):1473-8. PubMed ID: 9342069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.
    Poissy J; Aubry A; Fernandez C; Lott MC; Chauffour A; Jarlier V; Farinotti R; Veziris N
    Antimicrob Agents Chemother; 2010 Nov; 54(11):4765-71. PubMed ID: 20805388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pyrazinamide resistance-conferring mutations in pncA and the transmission of multidrug resistant TB in Georgia.
    Sengstake S; Bergval IL; Schuitema AR; de Beer JL; Phelan J; de Zwaan R; Clark TG; van Soolingen D; Anthony RM
    BMC Infect Dis; 2017 Jul; 17(1):491. PubMed ID: 28697808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalence and transmission of pyrazinamide resistant Mycobacterium tuberculosis in China.
    Xu P; Wu J; Yang C; Luo T; Shen X; Zhang Y; Nsofor CA; Zhu G; Gicquel B; Gao Q
    Tuberculosis (Edinb); 2016 May; 98():56-61. PubMed ID: 27156619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pyrazinamide Resistance Assays and Two-Month Sputum Culture Status in Patients with Multidrug-Resistant Tuberculosis.
    Velásquez GE; Calderon RI; Mitnick CD; Becerra MC; Huang CC; Zhang Z; Contreras CC; Yataco RM; Galea JT; Lecca LW; Murray MB
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6766-6773. PubMed ID: 27600032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
    Khan MY; Kinsara AJ; Osoba AO; Wali S; Samman Y; Memish Z
    Int J Antimicrob Agents; 2001 May; 17(5):415-8. PubMed ID: 11337231
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China.
    Pang Y; Zhu D; Zheng H; Shen J; Hu Y; Liu J; Zhao Y
    BMC Infect Dis; 2017 Nov; 17(1):711. PubMed ID: 29110640
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial.
    Diacon AH; Dawson R; von Groote-Bidlingmaier F; Symons G; Venter A; Donald PR; van Niekerk C; Everitt D; Winter H; Becker P; Mendel CM; Spigelman MK
    Lancet; 2012 Sep; 380(9846):986-93. PubMed ID: 22828481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis.
    Al-Mutairi NM; Ahmad S; Mokaddas E; Eldeen HS; Joseph S
    BMC Infect Dis; 2019 Jan; 19(1):3. PubMed ID: 30606116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoroquinolones and tuberculosis.
    Bryskier A; Lowther J
    Expert Opin Investig Drugs; 2002 Feb; 11(2):233-58. PubMed ID: 11829714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.